Amycretin vs Tirzepatide
Comparing Novo Nordisk's next-generation GLP-1/amylin unimolecular agonist amycretin with Eli Lilly's dual GIP/GLP-1 agonist tirzepatide.
Last updated: February 1, 2026
Amycretin
Tirzepatide
Overview
Amycretin and tirzepatide represent competing dual-agonist strategies for obesity. Amycretin combines GLP-1 with amylin receptor activity in a single molecule, while tirzepatide combines GLP-1 with GIP receptor activity. Both aim for superior weight loss versus GLP-1-only approaches, but through different secondary mechanisms.
Mechanism Comparison
| Aspect | Amycretin | Tirzepatide |
|---|---|---|
| Primary Target | GLP-1 receptor | GLP-1 receptor |
| Secondary Target | Amylin receptors | GIP receptor |
| Molecule Design | Unimolecular dual agonist | Single dual agonist |
| Satiety Pathways | Hypothalamus + brainstem | Hypothalamus |
Different Companion Mechanisms
Amycretin (GLP-1 + Amylin):
- Amylin signals meal completion
- Area postrema activation
- Complementary to GLP-1’s hypothalamic effects
- Same rationale as CagriSema
Tirzepatide (GLP-1 + GIP):
- GIP enhances insulin secretion
- Central effects on satiety
- Metabolic benefits beyond GLP-1
- Proven in clinical trials
Evidence Comparison
| Aspect | Amycretin | Tirzepatide |
|---|---|---|
| Development Phase | Phase 1/2 | FDA Approved |
| Human Data | Conference presentations | Extensive published |
| Regulatory Status | Early investigational | Approved (2022) |
| Real-world Data | None | Accumulating |
Efficacy Data
Amycretin (Phase 1 - Early Data)
| Timeframe | Weight Loss |
|---|---|
| 12 weeks | ~13% |
| Projected annualized | ~25% (speculative) |
Caveats: Small sample, short duration, extrapolation unreliable.
Tirzepatide (SURMOUNT-1)
| Dose | Weight Loss (72 weeks) |
|---|---|
| 5mg | ~15% |
| 10mg | ~19.5% |
| 15mg | ~22.5% |
Context: Phase 3 data with large sample sizes and long duration.
Regulatory Status
| Aspect | Amycretin | Tirzepatide |
|---|---|---|
| FDA Status | Investigational | Approved |
| Phase | 1/2 | Marketed |
| Indications | TBD | T2D, Obesity |
| Brand Names | N/A | Mounjaro, Zepbound |
| Approval Timeline | 2027+ (optimistic) | Already approved |
Development Timeline Gap
| Milestone | Amycretin | Tirzepatide |
|---|---|---|
| Phase 3 start | Not yet | Completed |
| NDA filing | Years away | 2022 (approved) |
| Market entry | 2027+ | 2022 |
| First-mover advantage | No | Yes |
Side Effect Profile
| Effect | Amycretin (Early) | Tirzepatide |
|---|---|---|
| Nausea | Common | Common |
| Vomiting | Common | Common |
| GI tolerability | Being characterized | Well-understood |
| Discontinuation | TBD | ~5-7% |
Strategic Context
Novo Nordisk Pipeline Position
| Compound | Status | Timeline |
|---|---|---|
| Semaglutide | Approved | Now |
| CagriSema | Phase 3 | 2025-2026 |
| Amycretin | Phase 1/2 | 2027+ |
Amycretin is the next-generation backup if CagriSema succeeds.
The Competitive Challenge
| Factor | Amycretin | Tirzepatide |
|---|---|---|
| Time to market | Years behind | Already available |
| Data maturity | Early | Extensive |
| Manufacturing | In development | Scaled (with shortages) |
| Physician familiarity | None | Growing |
Key Differences
| Factor | Amycretin | Tirzepatide |
|---|---|---|
| Secondary mechanism | Amylin | GIP |
| Brain targets | Hypothalamus + brainstem | Primarily hypothalamus |
| Evidence level | Phase 1 | Phase 3 + approved |
| Availability | Years away | Now |
| Developer | Novo Nordisk | Eli Lilly |
Potential Amycretin Advantages (Theoretical)
If amycretin delivers on early promise:
- Single injection combining GLP-1 + amylin
- Potentially >25% weight loss
- Different mechanism may benefit GIP non-responders
- Could be next-generation leader
But: This requires successful Phase 3 trials years from now.
Summary
- Amycretin shows promising early data (~13% at 12 weeks) but is years from potential approval
- Tirzepatide is the approved benchmark with ~22% weight loss and extensive safety data
- Different secondary mechanisms (amylin vs GIP) represent distinct approaches
- Tirzepatide’s first-mover advantage is substantial
- Amycretin represents Novo’s long-term competitive strategy
This comparison is for educational purposes only. Amycretin is in early-stage investigation. Consult a healthcare provider for treatment decisions.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.